title: Feverfew for migraine prophylaxis: a systematic review.
abstract: Feverfew has been studied for the treatment of migrane in several studies and the pharmacologic mechanisms are preliminarily understood. We performed a systematic review of randomized controlled trials and present the clinical findings and potential implications. The modality of data collection and reporting in the individual studies does not support a pooling of results, but does suggest benefit of feverfew in migraine prophylaxis for at least subsets of the population with the disorder. Pharmacologically, there is some potential for concern with long-term dosing given its cyclooxygenase-2 inhibiting effects and longer-term studies will be needed to ameliorate these concerns in coronary disease patients.
authors.affiliation: University of Connecticut, School of Pharmacy, Storrs, Connecticut, USA.
authors.forename: Elisa
authors.initials: E
authors.lastname: Saranitzky
authors.forename: C Michael
authors.initials: CM
authors.lastname: White
authors.forename: Erica L
authors.initials: EL
authors.lastname: Baker
authors.forename: William L
authors.initials: WL
authors.lastname: Baker
authors.forename: Craig I
authors.initials: CI
authors.lastname: Coleman
mesh_terms: D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008881:Migraine Disorders / Q000517:prevention & control*; D008517:Phytotherapy; D010936:Plant Extracts / Q000009:adverse effects / Q000627:therapeutic use*; D020903:Tanacetum parthenium / Q000009:adverse effects
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D010936:Plant Extracts